Indapamide

Generic Name
Indapamide
Brand Names
Coversyl
Drug Type
Small Molecule
Chemical Formula
C16H16ClN3O3S
CAS Number
26807-65-8
Unique Ingredient Identifier
F089I0511L
Background

The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced ...

Indication

Indapamide is a diuretic indicated for use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension. It may also be used to treat fluid and salt retention associated with congestive heart failure.

Associated Conditions
Hypertension, Recurrent Nephrolithiasis, Sodium and fluid retention
Associated Therapies
-

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

First Posted Date
2021-11-02
Last Posted Date
2024-10-16
Lead Sponsor
Alnylam Pharmaceuticals
Target Recruit Count
672
Registration Number
NCT05103332
Locations
🇬🇧

Clinical Trial Site, Torpoint, United Kingdom

🇺🇸

Clinical Trials Site, Beverly Hills, California, United States

🇺🇸

Clinical Trial site, Winston-Salem, North Carolina, United States

The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure

First Posted Date
2020-07-02
Last Posted Date
2021-12-08
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
200
Registration Number
NCT04455178
Locations
🇨🇳

Kunshan First Renmin Hospital, Kunshan, Jiangsu, China

🇨🇳

Changzhi Heping Hospital, Changzhi, Shanxi, China

🇨🇳

Dongtai Renmin Hospital, Dongtai, Jiangsu, China

and more 1 locations

Spironolactone Versus Indapamide in Obese and Hypertensive Patients

First Posted Date
2018-08-13
Last Posted Date
2019-12-03
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
400
Registration Number
NCT03626506
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

First Posted Date
2010-07-29
Last Posted Date
2014-06-24
Lead Sponsor
West China Hospital
Target Recruit Count
240
Registration Number
NCT01172431
Locations
🇨🇳

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM

First Posted Date
2009-09-18
Last Posted Date
2011-06-15
Lead Sponsor
LaborMed Pharma S.A.
Target Recruit Count
56
Registration Number
NCT00980187
Locations
🇷🇴

Cardiology, University and Emergency Hospital, Bucharest, Romania

© Copyright 2024. All Rights Reserved by MedPath